Cargando…

Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential

The emergence of Severe Acute Respiratory Syndrome Coronavirus (SARS‐CoV) led to a rapid response not only to contain the outbreak but also to identify possible therapeutic interventions, including the generation of human monoclonal antibodies (hmAbs). hmAbs may be used therapeutically without the d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coughlin, Melissa M., Prabhakar, Bellur S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2011
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256278/ https://www.ncbi.nlm.nih.gov/pubmed/21905149 http://dx.doi.org/10.1002/rmv.706

Ejemplares similares

Human monoclonal antibodies to SARS-coronavirus inhibit infection by different mechanisms
por: Coughlin, Melissa M., et al.
Publicado: (2009)

Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse(®)
por: Coughlin, Melissa, et al.
Publicado: (2007)

Human Monoclonal Antibodies against Highly Conserved HR1 and HR2 Domains of the SARS-CoV Spike Protein Are More Broadly Neutralizing
por: Elshabrawy, Hatem A., et al.
Publicado: (2012)

Neutralizing Monoclonal Antibodies as Promising Therapeutics against Middle East Respiratory Syndrome Coronavirus Infection
por: Han, Hui-Ju, et al.
Publicado: (2018)

Escape from Human Monoclonal Antibody Neutralization Affects In Vitro and In Vivo Fitness of Severe Acute Respiratory Syndrome Coronavirus
por: Rockx, Barry, et al.
Publicado: (2010)

Epitope mapping of severe acute respiratory syndrome coronavirus 2 neutralizing receptor binding domain-specific monoclonal antibodies
por: Maghsood, Faezeh, et al.
Publicado: (2022)

Neutralizing monoclonal antibodies against highly pathogenic coronaviruses
por: Xiang, Rong, et al.
Publicado: (2022)

Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants
por: Brehm, Thomas Theo, et al.
Publicado: (2022)

Neutralizing monoclonal antibody in patients with coronavirus disease 2019: an observational study
por: Liao, Xuejiao, et al.
Publicado: (2022)

Association of Neutralizing Antispike Monoclonal Antibody Treatment With Coronavirus Disease 2019 Hospitalization and Assessment of the Monoclonal Antibody Screening Score
por: Johnson, Patrick W., et al.
Publicado: (2023)

Potent universal beta-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing monoclonal antibody
por: Piepenbrink, Michael S., et al.
Publicado: (2022)

Determinants of having severe acute respiratory syndrome coronavirus 2 neutralizing antibodies in Egypt
por: El Rifay, Amira S., et al.
Publicado: (2021)

Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Combination Therapy in Patients With Coronavirus Disease 2019 and Primary Antibody Deficiency
por: Pulvirenti, Federica, et al.
Publicado: (2021)

Monoclonal Antibodies Targeting Ion Channels and Their Therapeutic Potential
por: Haustrate, Aurélien, et al.
Publicado: (2019)

COVID-19 Therapeutics: Use, Mechanism of Action, and Toxicity (Vaccines, Monoclonal Antibodies, and Immunotherapeutics)
por: Chary, Michael, et al.
Publicado: (2023)

Role of Immunoglobulin M and A Antibodies in the Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2
por: Klingler, Jéromine, et al.
Publicado: (2020)

Structure of Severe Acute Respiratory Syndrome Coronavirus Receptor-binding Domain Complexed with Neutralizing Antibody
por: Prabakaran, Ponraj, et al.
Publicado: (2006)

Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Infusions in High-Risk Outpatients
por: Piccicacco, Nicholas, et al.
Publicado: (2021)

Rapid Emergence of Potentially Transmissible Severe Acute Respiratory Syndrome Coronavirus 2 With Resistance to Combination Monoclonal Antibody Therapy
por: Jacobs, Jana L, et al.
Publicado: (2023)

Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults
por: Forte-Soto, Pablo, et al.
Publicado: (2023)

Sub-Domains of Ricin’s B Subunit as Targets of Toxin Neutralizing and Non-Neutralizing Monoclonal Antibodies
por: Yermakova, Anastasiya, et al.
Publicado: (2012)

Molecular targets for cystic fibrosis and therapeutic potential of monoclonal antibodies
por: Moni, Sivakumar S., et al.
Publicado: (2022)

Neutralizing Monoclonal Antibodies for Coronavirus Disease 2019 (COVID-19) in Pregnancy: A Case Series
por: Richley, Michael, et al.
Publicado: (2022)

Broad strategies for neutralizing SARS-CoV-2 and other human coronaviruses with monoclonal antibodies
por: Ling, Zhiyang, et al.
Publicado: (2022)

Preparation and characterization of a novel monoclonal antibody specific to severe acute respiratory syndrome-coronavirus nucleocapsid protein
por: Shin, Gu-Choul, et al.
Publicado: (2006)

Antigenic and cellular localisation analysis of the severe acute respiratory syndrome coronavirus nucleocapsid protein using monoclonal antibodies
por: Bussmann, Bianca M., et al.
Publicado: (2006)

An update of antispike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies
por: Chatterjee, Suparna, et al.
Publicado: (2022)

Epitope mapping of severe acute respiratory syndrome-related coronavirus nucleocapsid protein with a rabbit monoclonal antibody
por: Tian, Xingui, et al.
Publicado: (2021)

Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection
por: Crawford, Katharine H D, et al.
Publicado: (2020)

Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibodies in Egyptian Convalescent Plasma Donors
por: Gomaa, Mokhtar R., et al.
Publicado: (2020)

Characterization of neutralizing monoclonal antibodies recognizing a 15-residues epitope on the spike protein HR2 region of severe acute respiratory syndrome coronavirus (SARS-CoV)
por: Lai, Szu-Chia, et al.
Publicado: (2005)

SARS-CoV-2 monoclonal antibodies with therapeutic potential: Broad neutralizing activity and No evidence of antibody-dependent enhancement
por: Wang, Ying-Ting, et al.
Publicado: (2021)

Neutralizing monoclonal antibodies for treatment of COVID-19
por: Taylor, Peter C., et al.
Publicado: (2021)

Tackling COVID-19 with neutralizing monoclonal antibodies
por: Corti, Davide, et al.
Publicado: (2021)

Broadly neutralizing monoclonal antibodies for HIV prevention
por: Miner, Maurine D., et al.
Publicado: (2021)

Tackling COVID-19 with neutralizing monoclonal antibodies
por: Corti, Davide, et al.
Publicado: (2021)

Broadly neutralizing antibodies target the coronavirus fusion peptide
por: Dacon, Cherrelle, et al.
Publicado: (2022)

Broadly neutralizing antibodies target the coronavirus fusion peptide
por: Dacon, Cherrelle, et al.
Publicado: (2022)

Broadly Protective Neuraminidase-Based Influenza Vaccines and Monoclonal Antibodies: Target Epitopes and Mechanisms of Action
por: Abbadi, Nada, et al.
Publicado: (2023)

Nasal Spray of Neutralizing Monoclonal Antibody 35B5 Confers Potential Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern: A Small-Scale Clinical Trial
por: Lin, Yao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2r2cvsdh4h8h1ar609ep7l1vo0